<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03310957</url>
  </required_header>
  <id_info>
    <org_study_id>SGNLVA-002</org_study_id>
    <secondary_id>KEYNOTE 721</secondary_id>
    <secondary_id>2017-002289-35</secondary_id>
    <nct_id>NCT03310957</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer</brief_title>
  <official_title>Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies SGN-LIV1A with pembrolizumab in patients with triple-negative breast
      cancer. It will find out what side effects happen when participants get these two drugs. A
      side effect is anything the drugs do besides treating cancer. Pembrolizumab is a drug that
      can be used to treat triple-negative breast cancer. The trial will also find out if the drugs
      work to treat this type of cancer. Participants in this study have metastatic breast cancer.
      This means the cancer has spread to other parts of the body.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary goal of this study is to evaluate the combination of SGN-LIV1A, which targets
      LIV-1- expressing tumor cells, with the checkpoint inhibitor pembrolizumab for patients with
      unresectable locally-advanced or metastatic triple-negative breast cancer. These two drugs
      act through distinct and possibly complementary modes of action.

      This is a single-arm, open-label, multicenter trial. Patients given SGN-LIV1A and
      pembrolizumab during dose escalation will be monitored for frequency of dose-limiting
      toxicities to determine a recommended doses for expansion cohorts. In addition to safety
      measures, objective response rate, progression-free survival, overall survival, and other
      efficacy outcomes will be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed objective response rate</measure>
    <time_frame>Up to 18 weeks following last dose; approximately 1 year</time_frame>
    <description>Confirmed ORR as determined by investigator according to RECIST v 1.1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Through 1 month following last dose; approximately 10 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Through 1 month following last dose; approximately 10 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities</measure>
    <time_frame>Through 1 month following last dose; approximately 10 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 2.5 years following last dose</time_frame>
    <description>DOR as determined by investigator according to RECIST v 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>Up to 2.5 years following last dose</time_frame>
    <description>Proportion of patients with complete response (CR), partial response (PR), or stable disease (SD) as determined by investigator according to RECIST v 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 2.5 years following last dose</time_frame>
    <description>PFS as determined by investigator according to RECIST v 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2.5 years following last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>SGN-LIV1A plus pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SGN-LIV1A + pembrolizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGN-LIV1A</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>SGN-LIV1A plus pembrolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>IV infusion every 3 weeks</description>
    <arm_group_label>SGN-LIV1A plus pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic or locally-advanced, histologically documented TNBC (absence of HER2, ER,
             and PR expression)

          -  Have not previously received cytotoxic therapy for the treatment of unresectable
             locally-advanced breast cancer or metastatic breast cancer

          -  At least 6 months since prior treatment with curative intent and recurrence

          -  At least 1 tumor 10mm in diameter or greater OR lymph node of at least 15 mm in short
             axis

          -  ECOG performance status of 0 or 1

          -  Able to provide biopsy tissue for biomarker analysis

          -  Meet baseline laboratory data criteria

          -  Not pregnant. Must agree not to become pregnant until at least 6 months after ceasing
             study treatment

        Exclusion Criteria:

          -  Prior immune-oncology therapy

          -  Pre-existing neuropathy of at least Grade 2

          -  History of carcinomatous meningitis or active central nervous system (CNS) metastases.
             Patients are eligible if CNS metastases are adequately treated and patients have
             neurologically returned to baseline (except for residual signs or symptoms related to
             the CNS treatment) for at least 4 weeks prior to enrollment. Patients must be off
             corticosteroids.

          -  Received prior radiotherapy within 2 weeks of start of study treatment or have not
             adequately recovered from prior radiotherapy

          -  Active autoimmune disease requiring systemic treatment within the past 2 years

          -  History of interstitial lung disease

          -  Current pneumonitis or history of pneumonitis requiring steroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zejing Wang, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seattle Genetics Trial Information Support</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuzhat Siddiqui</last_name>
      <phone>205-975-2618</phone>
      <email>nuzhat@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Erica Stringer-Reasor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center / Samuel Oschin Comprehensive Cancer Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alyssa Ahorro</last_name>
      <phone>310-423-1047</phone>
      <email>AlyssaFrancesc.Ahorro@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Reva Basho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center University of California Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ritesh Parajuli</last_name>
      <phone>714-456-8614</phone>
      <email>rparajul@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Ritesh Parajuli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Irvine - Newport</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Dich</last_name>
      <phone>714-456-8614</phone>
      <email>mdich@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Ritesh Parajuli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers - Aurora</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rossen Roussev</last_name>
      <phone>303-418-7639</phone>
      <email>rossen.roussev@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Sami Diab</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Whittingham Cancer Center / Norwalk Hospital</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06856</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Evans</last_name>
      <phone>203-852-2996</phone>
      <email>sarah.evans@wchn.org</email>
    </contact>
    <investigator>
      <last_name>Linda Vahdat</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helen F. Graham Cancer Center / Christiana Care Health Systems</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise DeMaio</last_name>
      <phone>302-623-4500</phone>
      <email>denise.a.demaio@christianacare.org</email>
    </contact>
    <investigator>
      <last_name>Michael Guarino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Cancer Institute at Baptist Health, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Calvo</last_name>
      <phone>786-596-2000</phone>
      <email>MonicaCal@BaptistHealth.net</email>
    </contact>
    <investigator>
      <last_name>Grace Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AdventHealth Cancer Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Acker</last_name>
      <phone>407-303-4471</phone>
      <email>ingrid.acker@adventhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Sara Guyler</last_name>
      <phone>407-303-2024</phone>
      <email>sara.guyler@adventhealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Carlos Alemany</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Goodridge</last_name>
      <phone>813-745-4673</phone>
      <email>Dawn.Goodridge@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Hyo Heather Han</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olabusola Awoyemi</last_name>
      <phone>678-298-3242</phone>
      <email>oawoyemi@piedmontcancerinstitute.com</email>
    </contact>
    <investigator>
      <last_name>Rajni Sinha</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute / Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Falero</last_name>
      <phone>404-778-1900</phone>
      <email>vanessa.falero@emoryhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Jane Meisel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ingalls Cancer Care / Ingalls Memorial Hospital</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Marriott</last_name>
      <phone>708-339-4800</phone>
      <email>mmarriott@ingalls.org</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Gravitt</last_name>
      <phone>708-339-4800</phone>
      <email>Lgravitt@ingalls.org</email>
    </contact_backup>
    <investigator>
      <last_name>Danielle Sterrenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardinal Bernardin Cancer Center / Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Beth Bartolotta</last_name>
      <phone>708-327-3148</phone>
      <email>mbartolotta@luc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Gaye Moran</last_name>
      <phone>708-327-3229</phone>
      <email>gwmoran@luc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kathy Albain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Tait</last_name>
      <phone>410-328-3546</phone>
      <email>ntait@umm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Maha Khalil</last_name>
      <phone>410-328-2703</phone>
      <email>maha.khalil@umm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Katherine H. R. Tkaczuk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Piper Cancer Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacquelyn Underhill</last_name>
      <phone>612-863-4633</phone>
      <email>jacquelyn.underhill@allina.com</email>
    </contact>
    <contact_backup>
      <last_name>Lori Green</last_name>
      <phone>612-863-1093</phone>
      <email>lori.green@allina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michaela Tsai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Cancer Institute LLC</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Hutton</last_name>
      <phone>855-663-7524</phone>
      <email>clittrell@saint-lukes.org</email>
    </contact>
    <contact_backup>
      <last_name>Caroline Murray</last_name>
      <phone>855-663-7524</phone>
      <email>cwmurray@saint-lukes.org</email>
    </contact_backup>
    <investigator>
      <last_name>Timothy Pluard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summit Medical Group</name>
      <address>
        <city>Florham Park</city>
        <state>New Jersey</state>
        <zip>07932</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Mackenzie</last_name>
      <phone>973-436-1755</phone>
      <email>mmackenzie@smgnj.com</email>
    </contact>
    <investigator>
      <last_name>Steven Papish</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karwyn Gustafson, MD</last_name>
      <phone>505-272-4946</phone>
      <email>ksgustafson@salud.unm.edu</email>
    </contact>
    <investigator>
      <last_name>Ursa Brown-Glaberman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleni Andreopoulou</last_name>
      <phone>646-962-2064</phone>
      <email>ela9082@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Eleni Andreopoulou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Baylor Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rita Lopez</last_name>
      <phone>214-370-1000</phone>
      <email>rita.lopez2@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Sulema Silva</last_name>
      <phone>214-370-1000</phone>
      <email>sulema.silva@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Joyce O'Shaughnessy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Houston Memorial City</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Fru</last_name>
      <phone>713-467-1722</phone>
      <email>Nina.Fru@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Hina Nazir</last_name>
      <phone>713-467-1722</phone>
      <email>hina.nazir@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michelina Cairo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - San Antonio Medical Center Northeast</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Wilson</last_name>
      <phone>210-224-3820</phone>
      <email>kathryn.wilson@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Sharon Wilks</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Hazen</last_name>
      <email>SEH3AA@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick Dillon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gynakologisches Zentrum Bonn Friedensplatz</name>
      <address>
        <city>Bonn</city>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Christian Kurbacher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marien Hospital Bottrop</name>
      <address>
        <city>Bottrop</city>
        <zip>46236</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Hans Christian Kolberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stadtisches Klinikum Dessau</name>
      <address>
        <city>Dessau</city>
        <zip>06847</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Hermann Voss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Peter Fasching</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen-Mitte - Evang. Huyssens-Stiftung</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Sherko Kummel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitat Munchen</name>
      <address>
        <city>Munchen</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Rachel Wuerstlein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rotkreuzklinikum Munich</name>
      <address>
        <city>Munich</city>
        <zip>80637</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Claus Hanusch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts der Isar der Technischen Universitat Munchen</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Johannes Ettl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Young jin Choi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHA Bundang Medical Center</name>
      <address>
        <city>Seongnam</city>
        <zip>13496</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Yong Wha Moon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea Cancer Center Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>01802</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Hyun-Ah Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Seock-Ah Im</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Joo Hyuk Sohn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Young-Hyuck Im</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Joan Albanell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Mafalda Oliveira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Catala D'oncologia Hospitalet</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Rafael Villanueva Vazquez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaen</name>
      <address>
        <city>Jaen</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Pedro Sanchez Rovira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario La Coruna</name>
      <address>
        <city>La Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Silvia Antolin Novoa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico MD Anderson</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Laura Garcia Estevez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ruber Internacional</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Javier Cortes Castan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Luis Manso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HM Centro Integral Oncologico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seattle Genetics Trial Information Support</last_name>
      <phone>866-333-7436</phone>
      <email>clinicaltrials@seagen.com</email>
    </contact>
    <investigator>
      <last_name>Valentina Boni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 6, 2020</verification_date>
  <study_first_submitted>October 11, 2017</study_first_submitted>
  <study_first_submitted_qc>October 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2017</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Breast carcinoma</keyword>
  <keyword>Triple negative breast cancer</keyword>
  <keyword>Locally-advanced breast cancer</keyword>
  <keyword>Metastatic breast cancer</keyword>
  <keyword>Tumors, breast</keyword>
  <keyword>Breast tumors</keyword>
  <keyword>pembrolizumab</keyword>
  <keyword>LIV-1 protein, human</keyword>
  <keyword>Ladiratuzumab vedotin</keyword>
  <keyword>hLIV22-vcMMAE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

